Finn Søndergaard – CEO, Intsel Chimos, France
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Intsel Chimos is an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse and a partner of choice for hospitals. In 2010 and 2011, Intsel Chimos obtained orphan drug status from the EMA and the FDA respectively for a molecule intended for the treatment of gliomas (brain tumours), which marks the beginning of their transformation into a promising biotech player in France.
Contact
162 Bureaux de la Colline • 92213 SAINT CLOUD CEDEX • France
Tel: 01 49 11 66 80
Web: intselchimos.com
Email: contact@intselchimos.com
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
Virginie Beaumeunier, head of France’s CEPS, brings deep expertise in competition law and economic regulation to pharmaceutical pricing. Her background—including roles at the Finance Inspectorate and Competition Authority—shapes her approach…
Fabien Riolet leads Polepharma, France’s leading pharmaceutical manufacturing network, driving industrial sovereignty and innovation across 460 member companies. Under his leadership, it has evolved into a strategic hub for manufacturing…
With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR…
Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial…
France is betting big on industrial transformation. With its sweeping EUR 54 billion France 2030 investment plan, the government has laid down a clear ambition: to become a global leader…
As the global population ages and the incidence of vision-related conditions rises, ophthalmology is entering a transformative era. Beyond symptom management, the field is moving towards disease modification through cell…
Serge Picaud, the Executive Director of the Paris Vision Institute outlines a bold vision to transform ophthalmology through cutting-edge research and innovation. From pioneering the first successful optogenetic vision restoration…
Thomas Courbe, Director General for Enterprise at the French Ministry of Economy and Finance, has led France’s industrial transformation since 2019. He oversees, within the EURO 54 billion France 2030…
Julien Ettersperger, appointed in November 2023 as the first internal leader of Medicen, is steering the agency through a strategic transformation to establish Île-de-France as Europe’s leading health innovation hub.…
Professor Bana Jabri, Director of the Institut Imagine, brings a transatlantic perspective to advancing genetic medicine. After 25 years in the US, she now leads efforts in France to harness…
As global powers race to secure health sovereignty and industrial resilience, France stands at a crossroads. With rising regulatory asymmetries, fierce international competition, and mounting fiscal pressure on its pharmaceutical…
France is experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer committing over EUR 4 billion in new investments since 2023. This…
See our Cookie Privacy Policy Here
